The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.

Diabetes, Obesity & Metabolism
Shweta UrvaAxel Haupt

Abstract

The effect of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide on gastric emptying (GE) was compared to that of GLP-1RAs in non-clinical and clinical studies. GE was assessed following acute and chronic treatment with tirzepatide in diet-induced obese mice versus semaglutide or long-acting GIP analogue alone. Participants [with and without type 2 diabetes (T2DM)] from a phase 1, 4-week multiple dose study received tirzepatide, dulaglutide or placebo. GE was assessed by acetaminophen absorption. In mice, tirzepatide delayed GE to a similar degree to that achieved with semaglutide; however, these acute inhibitory effects were abolished after 2 weeks of treatment. GIP analogue alone had no effect on GE or on GLP-1's effect on GE. In participants with and without T2DM, once-weekly tirzepatide (≥5 and ≥4.5 mg, respectively) delayed GE after a single dose. This effect diminished after multiple doses of tirzepatide or dulaglutide in healthy participants. In participants with T2DM treated with an escalation schedule of tirzepatide 5/5/10/10 or 5/5/10/15 mg, a residual GE delay was still observed after multiple doses. These data suggest that tirzepatide's activ...Continue Reading

References

Nov 14, 1997·The American Journal of Physiology·N ImeryüzN B Ulusoy
Dec 18, 2003·American Journal of Physiology. Endocrinology and Metabolism·Juris J MeierMichael A Nauck
Jun 30, 2010·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·T EdholmP M Hellström
Jan 10, 2012·Diabetes, Obesity & Metabolism·J JelsingL Bjerre Knudsen
Nov 7, 2015·Physiological Reports·Andres AcostaAlan R Zinsmeister
Aug 30, 2018·Diabetes/metabolism Research and Reviews·Raffaella GentilellaAgostino Consoli
Nov 13, 2018·Current Opinion in Endocrinology, Diabetes, and Obesity·Michael Camilleri
Feb 12, 2019·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·Raj K GoyalHiroshi Mashimo

❮ Previous
Next ❯

Methods Mentioned

BETA
chip

Clinical Trials Mentioned

NCT02759107

Software Mentioned

graphpad prism

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.